BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9515821)

  • 1. Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells.
    Ragno P; Montuori N; Covelli B; Hoyer-Hansen G; Rossi G
    Cancer Res; 1998 Mar; 58(6):1315-9. PubMed ID: 9515821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase-type plasminogen-activator receptor associates to a cell surface molecule in monocytic cells.
    Ragno P; Montuori N; Rossi G
    Biochem Biophys Res Commun; 1996 Jul; 224(1):252-7. PubMed ID: 8694822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase-type plasminogen-activator and normal thyroid cell adhesion to the extracellular matrix.
    Ragno P; Montuori N; Salzano S; Rossi G
    Biochimie; 1999 Apr; 81(4):355-8. PubMed ID: 10401669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
    Reinartz J; Link J; Todd RF; Kramer MD
    Exp Cell Res; 1994 Oct; 214(2):486-98. PubMed ID: 7925643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
    Reuning U; Magdolen V; Hapke S; Schmitt M
    Biol Chem; 2003 Aug; 384(8):1119-31. PubMed ID: 12974381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid.
    Zanetti A; Stoppacciaro A; Marzullo A; Ciabatta M; Fazioli F; Prat M; Comoglio PM; Baroni CD; Ruco LP
    J Pathol; 1998 Nov; 186(3):287-91. PubMed ID: 10211118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor.
    Niedbala MJ; Bajetta S; Carbone R; Sartorelli AC
    Cancer Commun; 1990; 2(9):317-24. PubMed ID: 2169831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
    Champelovier P; Boucard N; Levacher G; Simon A; Seigneurin D; Praloran V
    Urol Res; 2002 Oct; 30(5):301-9. PubMed ID: 12389118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.
    Chambers SK; Wang Y; Gertz RE; Kacinski BM
    Cancer Res; 1995 Apr; 55(7):1578-85. PubMed ID: 7882368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
    Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
    Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human thyroid carcinoma cell invasion is controlled by the low density lipoprotein receptor-related protein-mediated clearance of urokinase plasminogen activator.
    Sid B; Dedieu S; Delorme N; Sartelet H; Rath GM; Bellon G; Martiny L
    Int J Biochem Cell Biol; 2006; 38(10):1729-40. PubMed ID: 16807059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
    Ulisse S; Baldini E; Toller M; Marchioni E; Giacomelli L; De Antoni E; Ferretti E; Marzullo A; Graziano FM; Trimboli P; Biordi L; Curcio F; Gulino A; Ambesi-Impiombato FS; D'Armiento M
    Eur J Cancer; 2006 Oct; 42(15):2631-8. PubMed ID: 16928445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dispase-mediated basal detachment of cultured keratinocytes induces urokinase-type plasminogen activator (uPA) and its receptor (uPA-R, CD87).
    Schaefer BM; Reinartz J; Bechtel MJ; Inndorf S; Lang E; Kramer MD
    Exp Cell Res; 1996 Nov; 228(2):246-53. PubMed ID: 8912717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
    Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells.
    Wickström SA; Veikkola T; Rehn M; Pihlajaniemi T; Alitalo K; Keski-Oja J
    Cancer Res; 2001 Sep; 61(17):6511-6. PubMed ID: 11522648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitronectin binding to urokinase receptor in human breast cancer.
    Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
    Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation.
    Shirasuna K; Saka M; Hayashido Y; Yoshioka H; Sugiura T; Matsuya T
    Cancer Res; 1993 Jan; 53(1):147-52. PubMed ID: 8380125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.